How much does a fractional CMO cost for a medical device company? Publicly advertised offers span everything from smaller strategic programs to embedded executive retainers costing five figures per month. But the real issue is not finding the lowest monthly fee. It is understanding what level of commercialization leadership you need, what that leader will actually own, and how the work will be measured.
Medical device marketing is not a typical digital acquisition problem. A company may need to convince physicians, hospital procurement, distributors, administrators, and finance teams, while coordinating approved claims, clinical evidence, and reimbursement considerations. A qualified fractional chief marketing officer can bring those workstreams into one commercial operating plan without requiring a full-time executive hire.
This guide compares publicly disclosed competitor pricing, explains the differences between advisory and embedded leadership, and shows what a sensible 90-day engagement should deliver. It also provides financial examples and KPI frameworks that medical device founders and CEOs can use when evaluating proposals.
Pricing checked November 4, 2026. Prices and offerings can change. Publicly advertised prices are provider-reported examples, not a representative industry benchmark or independently audited transactions. Financial models below are expressly illustrative.
Quick Answer: What Does a Medical Device Fractional CMO Cost?
For a medical device company, publicly advertised entry points include $4,000 per month at one MedTech-oriented fractional leadership firm and $8,000 per month at a dental and MedTech specialist whose typical engagements are listed at $12,000 to $20,000 per month. My own healthcare and MedTech fractional CMO service begins at $7,500 per month, with more involved operator-level work listed at $10,000 to $15,000 monthly.
Another medical device specialist advertises programs beginning at $2,500, but its page does not unambiguously label that number as a monthly retainer. It should not be presented as directly comparable to a monthly executive engagement without checking the included scope and payment period.
These examples show the breadth of available arrangements. They do not establish a market median. A two-hour weekly advisory role, a CMO managing your internal team, and an embedded leader preparing a multi-market product launch are different products.
What a CEO should budget: the leadership retainer plus the team, agency, research, creative, media, trade-show, travel, and software costs required to execute the agreed commercial plan. A CMO retainer is not automatically an all-inclusive marketing budget.
Verified Competitor Pricing: Medical Device and MedTech Fractional CMOs
The table below uses prices found directly on provider websites. Where language is ambiguous, the qualification is included rather than converted into an invented monthly rate.
| Provider | Public price | What the public offer says |
|---|---|---|
| MRC Medical | Programs starting at $2,500 | Describes a monthly growth plan and predetermined monthly hours, but does not clearly specify that the $2,500 starting amount is a monthly fee. |
| Marketize Group | Typically starts at $4,000/month | MedTech and healthcare fractional marketing leadership; monthly retainer with a stated 90-day minimum. |
| Charles Kirkland | Starts at $7,500/month | Healthcare and MedTech executive marketing leadership; defined 90-day starting period. Published operator-level options are $10,000 to $15,000/month. |
| Orr Consulting | Starts at $8,000/month; most $12,000 to $20,000/month | Dental and MedTech fractional leadership. Research and brand strategy projects are separate offerings. |
These prices were visible on the named companies' websites when reviewed. They are advertised starting prices or provider-described typical fees, not confirmed amounts actually paid by customers. Included hours, execution responsibilities, contract terms, and expense exclusions differ.
This is why a useful request for proposal should ask every candidate to price the same defined business problem and set of executive responsibilities. Otherwise, the cheapest proposal may simply omit the work your company needs most.
What Are You Actually Buying?
The title “fractional CMO” is used for several types of engagements. Price often reflects the amount of decision-making authority and accountability being delegated.
1. Executive advisory
The founder or existing marketing head owns day-to-day execution. The advisor helps with a launch decision, positioning, pricing discussions, vendor evaluation, or an operating review. This can be efficient when the company has a capable team and only needs strategic direction. It is not an adequate substitute for a missing leader if nobody can make and implement the resulting decisions.
2. Fractional executive leadership
The CMO owns the marketing roadmap, priorities, budget decisions, performance review, agency direction, and coordination with sales and other company functions. The internal team or specialist partners execute campaigns. This is the arrangement many growth-stage medical device companies are actually seeking.
3. Embedded commercialization leadership
The CMO participates more deeply in product-launch planning, market selection, customer research, sales enablement, pipeline review, board reporting, and vendor management. Work may also involve hospital account strategy or channel-partner coordination. More executive time and organizational responsibility generally require a higher fee.
4. Defined commercialization project
The engagement centers on a discrete outcome, such as a positioning and market-entry assessment, a 90-day launch plan, a marketing audit, or sales-enablement architecture. A project can be the right first purchase when the company is not ready for an ongoing leadership relationship.
My preferred model is simple: first identify the most expensive commercial constraint, then determine how much senior leadership the business needs to fix it. Do not buy 20 hours a month merely because a provider happens to sell 20 hours a month.
What Determines the Price of a Fractional CMO?
Commercialization stage
A company approaching an initial launch may need segmentation, positioning, buying-committee mapping, financial planning, and a controlled market-entry sequence. A company with national distribution and a team of reps may need sales enablement, campaign systems, attribution, and ongoing executive coordination. The number of moving parts affects scope.
Device and buying-process complexity
Marketing a cash-pay aesthetic device to independent practices differs from launching an implantable device into hospital systems. The buying journey may involve a surgeon champion, department head, value-analysis committee, finance, procurement, distributor, and implementation team. Those stakeholders require different proof and communications.
Regulatory and clinical coordination
The CMO should understand the boundaries of permitted promotion and organize reviews with qualified regulatory, clinical, quality, and legal personnel. That does not make the CMO your regulatory counsel, principal investigator, or reimbursement specialist.
Execution capacity
A fractional leader can get more done with a capable marketing team, sales operations support, and agency partners. If the company has no writer, designer, demand-generation resource, or CRM owner, extra execution funding may be necessary. Compare the full commercial team cost, not the CMO fee alone.
Intensity of leadership
Weekly consultation and a monthly report require less commitment than daily decisions, agency supervision, cross-functional meetings, new-market launch support, and executive reporting. Agree on availability, approval authority, deliverables, and escalation expectations before negotiating a fee.
Fractional CMO vs. Full-Time CMO vs. Marketing Agency
| Option | Primary responsibility | Best fit | Main limitation |
|---|---|---|---|
| Fractional CMO | Executive strategy, priorities, budgets, team leadership, commercial measurement | Growth-stage company needing senior ownership part-time | Time is shared; execution resources may cost extra |
| Full-time CMO | Dedicated executive leadership and broader organizational management | Multiple product lines, significant team and daily leadership needs | Salary, benefits, potential equity, recruiting time and long-term commitment |
| Marketing agency | Campaigns, design, SEO, paid media, research or other scoped execution | Company already has leadership and a defined plan | May not own companywide economic or commercialization decisions |
| Project consultant | Audit, recommendation, research or specific plan | One important decision or defined transition | Implementation may remain entirely with the client |
| Interim CMO | Temporary executive continuity, often with substantial time commitment | Replacing a departing executive or managing transition | Often structured around a temporary vacancy rather than flexible ongoing scope |
The decision is less about whether you can afford a CMO and more about what commercial decisions need an accountable owner. A company can waste $100,000 on advertising, conferences, or scattered agencies while debating a far smaller expenditure on leadership. That does not automatically justify hiring a fractional CMO, but it is a reason to compare the proposed fee against the value of better decisions.
See my complete Fractional CMO guide for healthcare and MedTech for the broader differences between the roles.
The First 90 Days: What a Medical Device Fractional CMO Should Deliver
An initial 90-day plan should not promise to close hospital contracts before the actual purchasing cycle permits them. It should establish the commercial operating system, clarify the decisions, remove avoidable bottlenecks, and launch work that can be measured.
Days 1–30: Diagnose the commercialization constraint
- Interview leadership across sales, marketing, product, clinical, regulatory, finance and operations.
- Review target markets, customer segments, buying committees, competitors, differentiation and the available clinical evidence.
- Inspect the active pipeline, opportunity stages, lost deals, evaluation starts and sales-cycle timing.
- Audit positioning, website, paid channels, trade-show plans, sales materials, customer research, agencies and reporting.
- Identify product-claim approval dependencies with the appropriate regulatory and legal owners.
- Review marketing spend, vendor commitments, funnel economics and team capability.
- Establish baseline definitions for the KPIs the CEO and commercial team will use.
Expected output by day 30: a commercialization diagnosis, prioritized opportunity list, marketing economics baseline, initial dashboard and a decision memo showing what to stop, improve and build.
Days 31–60: Architect the growth system
- Choose the primary beachhead segment and the next logical expansion opportunities.
- Develop a positioning framework that separates clinical, workflow and economic value while respecting approved claims.
- Map the buying journey, objections, evidence requirements, evaluations and internal handoffs.
- Define sales enablement needs for physicians, administrators, procurement, distributors and partners where relevant.
- Develop a channel plan for search, content, account-based demand, industry events, referrals, partnerships and other appropriate programs.
- Set a 12-month budget view and a 90-day execution budget with named owners.
- Build a weekly reporting cadence and an executive KPI scorecard.
Expected output by day 60: messaging architecture, prioritized go-to-market roadmap, budget, owner matrix, launch milestones and a functioning measurement plan.
Days 61–90: Execute, inspect and adjust
- Launch the highest-priority approved demand and sales-support programs.
- Deploy and test sales materials, qualification flows, content or account campaigns.
- Work with sales operations on lead ownership, follow-up discipline, pipeline stages and attribution.
- Review the first observed indicators against the agreed baseline.
- Adjust spend and priorities based on lead quality, buyer response and actual commercial constraints.
- Deliver a board-ready summary of work completed, risks, spend, KPIs and next-quarter decisions.
Expected output by day 90: implemented priority workstreams, measurement cadence, accountable owners, a tested commercial hypothesis and a defensible plan for the next quarter.
Those deliverables can be adapted to your product category. An established capital-equipment business and a newly authorized specialty device should not be given identical 90-day programs.
How Much Does a 90-Day Fractional CMO Engagement Cost?
My published healthcare and MedTech service starts at $7,500 per month. The separately published operator-level option runs $10,000 to $15,000 per month, depending on scope. The following calculations illustrate leadership fees only.
| Monthly leadership fee | Three-month equivalent | 12-month equivalent |
|---|---|---|
| $7,500 | $22,500 | $90,000 |
| $10,000 | $30,000 | $120,000 |
| $12,500 | $37,500 | $150,000 |
| $15,000 | $45,000 | $180,000 |
These are simple fee multiples, not custom proposals, discounts or guaranteed scope. Each company needs a written statement of work covering availability, review cadence, responsibilities and separate execution costs.
A realistic total-program example
Suppose a company budgets $10,000 per month for senior marketing leadership over 90 days, plus $15,000 in approved demand programs, $9,000 in content and creative work, and $6,000 in research, measurement or implementation support. The total hypothetical program allocation is $60,000: $30,000 of leadership and $30,000 of execution and support.
Compare that with a plan containing a $30,000 executive fee but no money or staffing for actual implementation. The more complete proposal can appear more expensive while being considerably more useful.
Be equally careful about double-counting. If your existing agency retainer already includes content production and tracking, those costs should not be added a second time merely to inflate the budget.
How Do You Measure the Value of a Medical Device Fractional CMO?
A useful measurement system separates early indicators, pipeline progression, and realized financial outcomes. A hospital sale may take much longer than a quarter, so a 90-day scorecard should not pretend every important result can be converted into immediate booked revenue.
| KPI category | Measures | Question answered |
|---|---|---|
| Market focus | Target accounts reached; qualified stakeholder engagement; segment fit | Are we talking to the right buyers? |
| Demand | Qualified requests; meetings accepted; sales-accepted leads; relevant opportunities created | Are programs creating real sales conversations? |
| Sales progression | Demo-to-evaluation conversion; evaluation starts; pilot outcomes; proposal conversion; stage velocity | Is demand progressing toward adoption? |
| Commercial economics | Spend by program; cost per qualified opportunity; sourced and influenced pipeline; contribution on realized sales | Is the program economically defensible? |
| Execution | Approved asset deployment; rep adoption; milestone completion; budget variance; CRM quality | Is the company actually executing the plan? |
| Leadership | Clear owners; operating cadence; priority decisions; forecast visibility | Is executive coordination improving? |
Definitions are critical. An inquiry is not automatically a qualified opportunity. A hospital trial is not booked revenue. A marketing-influenced opportunity is not necessarily marketing-created. Report these separately and reconcile commercial activity with sales and finance.
Illustrative contribution break-even
Suppose a device sale generates $12,000 in collected revenue and $4,000 in contribution after variable product costs. A $30,000 leadership fee would require 7.5 incremental device sales of that contribution value to break even on the leadership fee alone, so eight incremental completed sales would exceed it in this simplified model.
This is not a promised return. It excludes execution costs, collection delays, sales resources and time to close, and it assumes a credible way to establish that sales were truly incremental. For a sound commercial evaluation, divide incremental contribution from attributable business improvement by the fully loaded program investment over an appropriate time horizon.
Why Medical Device Commercialization Requires More Than Generic Marketing
Regulatory authorization is not commercial adoption
Medical device companies need to communicate accurately about their products' regulatory status. The FDA explicitly warns that establishment registration and device listing do not indicate clearance or approval. Depending on the classification and applicable pathway, devices may need clearance, approval, another type of authorization, or may qualify for an exemption.
A CMO can coordinate launch and messaging strategy around the product's actual status, but product claims should be reviewed by the qualified regulatory and legal owners. Claims and evidence cannot be treated like ordinary ad-copy experiments.
Reimbursement can change the buyer's economic case
The Centers for Medicare & Medicaid Services distinguishes coding, coverage and payment as related but separate matters. A new code alone does not mean a payer must cover a device or that a specific payment will follow. A device's economic story may require a coordinated approach involving reimbursement specialists and the company's market-access team.
Hospital buyers are not one audience
Winning a physician champion may create interest, but not automatically satisfy the needs of procurement, finance, nursing, a value-analysis committee, or a hospital system's contracting process. The sales and marketing system should provide appropriate evidence for each stakeholder and make the path from interest to purchase visible.
Ethical interactions matter
Events, clinical education, relationships with healthcare professionals and other sales-support activity need appropriate compliance review. The AdvaMed Code of Ethics offers an industry framework for ethical interactions with healthcare professionals. The CMO coordinates commercial work within the company's compliance structure rather than bypassing it.
These issues explain why a generic marketing quote and a medical-device commercialization leadership proposal may differ substantially, even when both carry the same fractional CMO job title.
When Should a Medical Device Startup Hire a Fractional CMO?
A fractional CMO may be valuable when the CEO has become the default head of marketing, several agencies are producing disconnected work, sales needs credible evidence-backed messaging, or the company's launch plans are moving faster than its internal leadership capacity.
The model is particularly relevant when a company has achieved an important product milestone, has at least some execution resources, and needs senior coordination but is not yet ready to hire a full-time CMO.
When advisory or a diagnostic may be a better first step
If the business lacks clarity about its market, regulatory status, commercial viability, or core constraint, a defined assessment may be more suitable than an ongoing retainer. Likewise, if a startup cannot fund any agency, marketing employee or production resources, a fractional CMO may spend most of the engagement producing a plan that nobody can execute.
When a full-time CMO makes sense
A full-time executive becomes more compelling when there are multiple product lines, expanding markets, a substantial marketing team, frequent strategic decisions, and enough ongoing leadership work to justify a dedicated position.
There is no universal revenue threshold that decides this automatically. Review organizational complexity, available budget, executive workload and the cost of delayed decisions.
What Should You Ask Before Signing a Fractional CMO Agreement?
- What medical device categories and channels have you personally worked with?
- Who will lead the work? Will the principal or a junior account team attend weekly reviews?
- What operating decisions will you own, and what authority remains with the CEO?
- What are the specific deliverables at 30, 60 and 90 days?
- How do you work with regulatory, quality, clinical, legal and reimbursement teams?
- What internal team, agency and vendor capacity do you require to execute?
- Which services and expenses are excluded from the retainer?
- How will you define qualified pipeline and distinguish marketing-sourced from influenced revenue?
- How do you handle long hospital sales cycles and delayed commercial milestones?
- Who owns the content, data, ad accounts and operating documents after the contract ends?
- What is the contract's initial term, notice period and scope-change process?
- What would make you recommend that we do not hire a fractional CMO?
A credible provider should be willing to discuss the answers before sending an agreement. The best engagement has clear ownership, appropriate access, transparent economics, and defined evidence for deciding what happens next.
Frequently Asked Questions
What is the average fractional CMO fee in MedTech?
There is no reliable representative average specific to medical-device fractional CMOs available from the small set of public provider prices reviewed here. Marketize advertises a starting price of $4,000 per month, Charles Kirkland advertises $7,500 per month, and Orr Consulting advertises a starting $8,000 per month with most engagements at $12,000 to $20,000 per month. Fees depend on scope and executive involvement.
What is the usual minimum engagement?
It varies. Marketize publishes a 90-day minimum. My healthcare and MedTech service begins with a defined 90-day leadership period. Confirm specific terms in the proposal before signing.
Does the retainer include media buying or creative production?
Not necessarily. On my service page, copy, creative, media buying, development and campaign execution are handled by the company's team, specialized partners or separately scoped resources. Other providers vary. Ask for a complete budget.
Can a fractional CMO manage our current marketing agency?
Yes. Agency leadership, prioritization, performance reporting and cross-functional coordination are common executive responsibilities, provided the scope includes that oversight.
Is a fractional CMO the same as a medical device marketing consultant?
No. A consultant may deliver research or advice for a defined problem. A fractional CMO generally has ongoing accountability for strategy, people, budget, priorities and implementation oversight.
Can a fractional CMO lead an FDA-cleared medical device launch?
Yes, a qualified fractional CMO can coordinate market positioning, launch sequencing, communication planning and sales enablement for an appropriately authorized product. Regulatory and legal specialists remain responsible for their own review and approval roles.
What should change after the first 90 days?
You should have clearer priorities, a functioning commercial dashboard, documented positioning and channel decisions, accountable implementation owners, and evidence of progress on leading indicators. A 90-day engagement does not guarantee a hospital purchase or revenue milestone that depends on a longer buying cycle.
How do we calculate ROI?
Compare attributable incremental contribution over an appropriate time horizon with the full program cost, while separately examining pipeline quality, conversion, commercial timing and the operating system built. Avoid treating every company sale as the CMO's independent achievement.
My Recommendation for Medical Device CEOs
If your company needs one senior leader to connect positioning, commercialization strategy, demand creation, sales enablement, people, budgets and measurement, fractional marketing leadership can be a practical alternative to hiring a full-time executive prematurely.
But do not hire the title. Hire a defined set of responsibilities and decisions. Ask what needs to be true after 90 days, which barriers must be removed, what the entire execution plan costs, and who will own each measurable outcome.
My Fractional CMO leadership engagement is structured around that operating responsibility, with starting pricing published openly. If you are evaluating the right level of support for your device business, book an introductory strategy conversation. We can discuss whether the next move is a focused diagnosis, a commercialization roadmap, or ongoing fractional leadership.
You can also review my Fractional CMO guide for healthcare and MedTech companies and growth advisory services before deciding.
Planning commercialization as well as marketing leadership? Read the medical device commercialization strategy guide for a 90-day executive roadmap, six-month budget example, hospital procurement considerations, and account-level KPIs.
Sources and Pricing Methodology
Last reviewed November 4, 2026. This article uses publicly stated provider prices rather than a broad market survey. Scope, hours, price changes and contract terms must be confirmed with each provider. Arithmetic examples and 90-day deliverables are frameworks, not claims about competitors' client outcomes.
- MRC Medical, Fractional CMO service and advertised starting program
- Marketize Group, Fractional Marketing Leadership and pricing FAQ
- Orr Consulting, Dental and MedTech Marketing Consultant pricing
- Charles Kirkland, Fractional CMO service and current starting price
- Charles Kirkland, published engagement options
- FDA, Important Reminders about Registration and Listing
- CMS, Medical Technology Companies: Getting Started
- AdvaMed, Code of Ethics
.png)